Anti-ctla4 antibodies and methods of making and using the same
Patent Information
- Application Number
- HK62026127032
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-04-13
- Filing Date
- 2026-08-04
- Publication Date
- 2026-09-11
Smart Images

Figure 00000262_0000 
Figure 00000263_0000 
Figure 00000263_0001
Abstract
Description
Abstract This article provides antibodies (or antigen-binding fragments thereof) that bind to human CTLA4 and have an enhancing effector function (e.g., antibodies that bind to human CTLA4), masked antibodies that bind to human CTLA4 (e.g., activated antibodies), nucleic acids encoding such antibodies, pharmaceutical compositions thereof, and methods for therapeutic use thereof (e.g., for cancer treatment).
Claims
1.An isolated antibody that binds to human CTLA4, wherein the antibody comprises a heavy chain comprising a heavy chain variable region (VH) and a light chain comprising a light chain variable region (VL) , wherein the heavy chain comprises a heavy chain constant region comprising a human IgG1 Fc region, wherein the heavy chain constant region comprises one or more substitutions selected from the group consisting of a L235V substitution, a S239D substitution, an F243L substitution, an R292P substitution, an S298A substitution, a Y300L substitution, a V305I substitution, a K326A substitution, an A330L substitution, an I332E substitution, an E333A substitution, a K334A substitution, and a P396L substitution, wherein the residue numbering is according to EU numbering.2.The antibody of claim 1, wherein1) the VH comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2, a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3, and the VL comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6;2) the VH comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 12, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 13, a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 14, and the VL comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 15, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 16, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 17;3) the VH comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 44, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 45, a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 53, and the VL comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 54, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 16, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 55; or4) the VH comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 44, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 45, a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 46, and the VL comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 47, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 48.3.The isolated antibody of claim 1 or 2, wherein: 1) the VH comprises the amino acid sequence of SEQ ID NO: 74, and / or the VL comprises the amino acid sequence of SEQ ID NO: 75; 2) the VH comprises the amino acid sequence of SEQ ID NO: 66, and / or the VL comprises the amino acid sequence of SEQ ID NO: 67; 3) the VH comprises the amino acid sequence of SEQ ID NO: 84, and / or the VL comprises the amino acid sequence of SEQ ID NO: 85; or 4) the VH comprises the amino acid sequence of SEQ ID NO: 80, and / or the VL comprises the amino acid sequence of SEQ ID NO: 81.4.The isolated antibody of any one of claims 1-3, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 91, and the light chain comprises the amino acid sequence of SEQ ID NO: 90.5.The isolated antibody of any one of claims 1-3, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 91 without the C-terminal lysine, and the light chain comprises the amino acid sequence of SEQ ID NO: 906.The isolated antibody of any one of claims 1-5, wherein the antibody comprises two heavy chains and two light chains, wherein each human IgG1 Fc domain of the heavy chains comprises:i) an S298A substitution, an E333A substitution, and a K334A substitution;ii) an S298A substitution, an E333A substitution, a K334A substitution, and a K326A substitution;iii) an F243L substitution;iv) an F243L substitution, an R292P substitution, a Y300L substitution, and a P396L substitution;v) an F243L substitution, an R292P substitution, a Y300L substitution, a V305I substitution, and a P396L substitution;vi) an F243L substitution, an R292P substitution, a Y300L substitution, a L235V substitution, and a P396L substitution;vii) a S239D substitution, an I332E substitution, and an A330L substitution; orviii) a S239D substitution and an I332E substitution.7.The isolated antibody of claim 6, wherein each human IgG1 Fc domain comprises a S239D substitution and an I332E substitution.8.The isolated antibody of claim 6, wherein each human IgG1 Fc domain comprises a S239D substitution, an I332E substitution, and an A330L substitution.9.The isolated antibody of claim 6, wherein each human IgG1 Fc domain comprises an F243L substitution, an R292P substitution, a Y300L substitution, a V305I substitution, and a P396L substitution.10.The isolated antibody of any one of claims 1-9, wherein the isolated antibody induces antibody-dependent cell cytotoxicity (ADCC) against a CTLA4-expressing human cell or a human Treg cell, wherein the ADCC activity of the isolated antibody is higher than that of a control antibody comprising a human IgG1 Fc region that does not comprise the substitutions, and / or wherein the ADCC activity of the isolated antibody is higher than the ADCC activity of ipilimumab.11.A masked antibody that binds to human CTLA4, comprising a masking peptide (MP) and an antibody, wherein the antibody comprises a heavy chain comprising a heavy chain variable region (VH) and a light chain comprising a light chain variable region (VL) , wherein the MP is linked to the N-terminal of the VH or VL, wherein the MP comprises, from N-terminus to C-terminus, a masking unit (MU) and a linkage unit (LU) , wherein the MU comprises an amino acid sequence selected from the list consisting of SEQ ID NOs: 146-151, and wherein1) the VH comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2, a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3, and the VL comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6;2) the VH comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 12, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 13, a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 14, and the VL comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 15, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 16, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 17;3) the VH comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 44, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 45, a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 53, and the VL comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 54, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 16, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 55; or4) the VH comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 44, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 45, a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 46, and the VL comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 47, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 48.12.The masked antibody of claim 11, wherein the MP further comprises an N-terminal unit (NU) linked to the N-terminal of the MU.13.The masked antibody of claim 12, wherein the N-terminal unit is about 1-10 amino acid residues long.14.The masked antibody of claim 12, wherein the N-terminal unit comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 143-145.15.The masked antibody of any one of claims 11-14, wherein the LU does not comprise a cleavage site.16.The masked antibody of claim 15, wherein the LU comprises a linker.17.The masked antibody of claim 16 wherein the linker comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 155-161.18.The masked antibody of claim 16 wherein the linker comprises the amino acid sequence of SEQ ID NO: 159.19.The masked antibody of any one of claims 11-14, wherein the masked antibody is an activatable antibody.20.The masked antibody of claim 19, wherein the LU comprises at least a first cleavage site (C1) .21.The masked antibody of claim 20, wherein the first cleavage site (C1) is a protease cleavage site for a protease selected from the group consisting of urokinase-type plasminogen activator (uPA) , matrix metalloproteinase-1 (MMP-1) , MMP-2, MMP-3, MMP-8, MMP-9, MMP-14, Tobacco Etch Virus (TEV) protease, plasmin, Thrombin, Factor X, PSA, PSMA, Cathepsin D, Cathepsin K, Cathepsin S, ADAM10, ADAM12, ADAMTS, Caspase-1, Caspase-2, Caspase-3, Caspase-4, Caspase-5, Caspase-6, Caspase-7, Caspase-8, Caspase-9, Caspase-10, Caspase-11, Caspase-12, Caspase-13, Caspase-14, and TACE.22.The masked antibody of claim 20 or 21, wherein the first cleavage site (C1) comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 152-154.23.The masked antibody of any one of claims 20-22, wherein the LU further comprises a second cleavage site (C2) .24.The masked antibody of claim 23, wherein the second cleavage (C2) site is a protease cleavage site for a protease selected from the group consisting of urokinase-type plasminogen activator (uPA) , matrix metalloproteinase-1 (MMP-1) , MMP-2, MMP-3, MMP-8, MMP-9, MMP-14, Tobacco Etch Virus (TEV) protease, plasmin, Thrombin, Factor X, PSA, PSMA, Cathepsin D, Cathepsin K, Cathepsin S, ADAM10, ADAM12, ADAMTS, Caspase-1, Caspase-2, Caspase-3, Caspase-4, Caspase-5, Caspase-6, Caspase-7, Caspase-8, Caspase-9, Caspase-10, Caspase-11, Caspase-12, Caspase-13, Caspase-14, and TACE.25.The masked antibody of claim 23 or 24, wherein the second cleavage site (C2) comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 152-154.26.The masked antibody of any one of claims 23-25, wherein the first and second cleavage sites are different.27.The masked antibody of any one of claims 19-26, wherein the LU further comprises a first linker.28.The masked antibody of claim 27, wherein the first linker comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 155-161.29.The masked antibody of claim 27 or 28, wherein the LU further comprises a second linker (L2) .30.The masked antibody of claim 29, wherein the second linker comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 155-161.31.The masked antibody of any one of claims 27-30, wherein the LU comprises, from N-terminus to C-terminus:1) the first cleavage site (C1) , the first linker (L1) , the second cleavage site (C2) , and the second linker (L2) ; or2) the first linker (L1) , the first cleavage site (C1) , and the second linker (L2) .32.The masked antibody of any one of claims 11-31, wherein the LU comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 99-103.33.The masked antibody of any one of claims 11-31, whereinthe MU comprises the amino acid sequence of SEQ ID NO: 146, and the LU comprises the amino acid sequence of SEQ ID NO: 99;the MU comprises the amino acid sequence of SEQ ID NO: 147, and the LU comprises the amino acid sequence of SEQ ID NO: 99;the MU comprises the amino acid sequence of SEQ ID NO: 148, and the LU comprises the amino acid sequence of SEQ ID NO: 99;the MU comprises the amino acid sequence of SEQ ID NO: 149, and the LU comprises the amino acid sequence of SEQ ID NO: 99;the MU comprises the amino acid sequence of SEQ ID NO: 150, and the LU comprises the amino acid sequence of SEQ ID NO: 99;the MU comprises the amino acid sequence of SEQ ID NO: 148, and the LU comprises the amino acid sequence of SEQ ID NO: 100;the MU comprises the amino acid sequence of SEQ ID NO: 148, and the LU comprises the amino acid sequence of SEQ ID NO: 101;the MU comprises the amino acid sequence of SEQ ID NO: 148, and the LU comprises the amino acid sequence of SEQ ID NO: 102;the MU comprises the amino acid sequence of SEQ ID NO: 148, and the LU comprises the amino acid sequence of SEQ ID NO: 101;the MU comprises the amino acid sequence of SEQ ID NO: 151, and the LU comprises the amino acid sequence of SEQ ID NO: 100;the MU comprises the amino acid sequence of SEQ ID NO: 151, and the LU comprises the amino acid sequence of SEQ ID NO: 101;the MU comprises the amino acid sequence of SEQ ID NO: 150, and the LU comprises the amino acid sequence of SEQ ID NO: 101;the MU comprises the amino acid sequence of SEQ ID NO: 150, and the LU comprises the amino acid sequence of SEQ ID NO: 102;the MU comprises the amino acid sequence of SEQ ID NO: 150, and the LU comprises the amino acid sequence of SEQ ID NO: 102;the MU comprises the amino acid sequence of SEQ ID NO: 150, and the LU comprises the amino acid sequence of SEQ ID NO: 103; orthe MU comprises the amino acid sequence of SEQ ID NO: 150, and the LU comprises the amino acid sequence of SEQ ID NO: 103.34.The masked antibody of any one of claims 11-33, wherein the masking peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 162-177.35.The masked antibody of any one of claims 11-34, wherein 1) the VH comprises the amino acid sequence of SEQ ID NO: 74, and / or the VL comprises the amino acid sequence of SEQ ID NO: 75; 2) the VH comprises the amino acid sequence of SEQ ID NO: 66, and / or the VL comprises the amino acid sequence of SEQ ID NO: 67; 3) the VH comprises the amino acid sequence of SEQ ID NO: 84, and / or the VL comprises the amino acid sequence of SEQ ID NO: 85; or 4) the VH comprises the amino acid sequence of SEQ ID NO: 80, and / or the VL comprises the amino acid sequence of SEQ ID NO: 81.36.The masked antibody of any one of claims 11-35, wherein the masked antibody is a Fab fragment, an scFv, a F (ab′) 2 fragment, or an Fv fragment.37.The masked antibody of any one of claims 11-35, wherein the antibody comprises two heavy chains and two light chains, wherein each human IgG1 Fc domain of the heavy chain comprises one or more substitutions selected from the group consisting of a L235V substitution, a S239D substitution, an F243L substitution, an R292P substitution, an S298A substitution, a Y300L substitution, a V305I substitution, a K326A substitution, an A330L substitution, an I332E substitution, an E333A substitution, a K334A substitution, and a P396L substitution, wherein the residue numbering is according to EU numbering.38.The masked antibody of claim 37, wherein each human IgG1 Fc domain comprises:i) an S298A substitution, an E333A substitution, and a K334A substitution;ii) an S298A substitution, an E333A substitution, a K334A substitution, and a K326A substitution;iii) an F243L substitution;iv) an F243L substitution, an R292P substitution, a Y300L substitution, and a P396L substitution;v) an F243L substitution, an R292P substitution, a Y300L substitution, a V305I substitution, and a P396L substitution;vi) an F243L substitution, an R292P substitution, a Y300L substitution, a L235V substitution, and a P396L substitution;vii) a S239D substitution, an I332E substitution, and an A330L substitution; orviii) a S239D substitution and an I332E substitution.39.The masked antibody of claim 38, wherein each human IgG1 Fc domain comprises a S239D substitution and an I332E substitution.40.The masked antibody of claim 38, wherein each human IgG1 Fc domain comprises a S239D substitution, an I332E substitution, and an A330L substitution.41.The masked antibody of claim 38, wherein each human IgG1 Fc domain comprises an F243L substitution, an R292P substitution, a Y300L substitution, a V305I substitution, and a P396L substitution.42.The masked antibody of any one of claims 37-41, wherein the heavy chains each comprise an amino acid sequence selected from the group consisting of SEQ ID NOS: 104-105, and the light chains each comprise an amino acid sequence selected from the group consisting of SEQ ID NOS: 106-121.43.The masked antibody of claim 42, wherein the heavy chains each comprise the amino acid sequence of SEQ ID NO: 105, and the light chains each comprise the amino acid sequence of SEQ ID NO: 121.44.The masked antibody of any one of claims 37-43, wherein the masked antibody induces antibody-dependent cell cytotoxicity (ADCC) against a CTLA4-expressing human cell or a human Treg cell, wherein the ADCC activity of the isolated antibody is higher than that of a control antibody comprising a human IgG1 Fc region that do not comprise the substitutions, and / or wherein the ADCC activity of the isolated antibody is higher than the ADCC activity of ipilimumab.45.An isolated polynucleotide encoding one or more polypeptide chains of the isolated antibody of any one of claims 1-10, or the masked antibody of any one of claims 11-44.46.A vector comprising the polynucleotide of claim 45.47.The vector of claim 46, wherein the vector is an expression vector and / or a display vector.48.A host cell comprising the polynucleotide or vector of any one of claims 45-47.49.The host cell of claim 48, wherein the host cell is a eukaryotic cell.50.The host cell of claim 48 or 49, wherein the host cell is a Chinese Hamster Ovary (CHO) cell.51.A method of making an antibody or masked antibody comprising culturing the host cell of any one of claims 48-50 under conditions suitable for producing the antibody or activatable antibody.52.The method of claim 51, further comprising recovering the antibody or masked antibody produced by the cell.53.A pharmaceutical composition comprising the antibody of any one of claims 1-10, or the masked antibody of any one of claims 11-44, and a pharmaceutically acceptable carrier.54.A method of treating or delaying progression of a cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of the antibody of any one of claims 1-10, the masked antibody of any one of claims 11-44, or the pharmaceutical composition of claim 53.55.A method of reducing size of a solid tumor in a subject in need thereof, wherein the solid tumor has a size of about 400-1000 mm3, the method comprises administering to the subject an effective amount of the antibody of any one of claims 1-10, the masked antibody of any one of claims 11-44, or the pharmaceutical composition of claim 53.56.A method of reducing on-target off-tumor toxicity in a subject having a cancer in need thereof, wherein the method comprises administering to the subject an effective amount of the masked antibody of any one of claims 11-44.57.The method of any one of claims 54-56, wherein the tumor is a colorectal tumor or a lung tumor.58.The method of any one of claims 54-57, wherein the tumor is a cold tumor.59.The method of claim 58, wherein the cold tumor is selected from the group consisting of pancreatic cancer, ovarian cancer, and head and neck cancer.60.The method of any one of claims 54-59, further comprising administering to the subject an effective amount of at least one additional therapeutic agent.61.The method of claim 60, wherein the at least one additional therapeutic agent is selected from the group consisting of viral gene therapy, immune checkpoint inhibitors, target therapies, radiation therapies, vaccination therapies, and chemotherapies.62.The method of claim 61, wherein the at least one additional therapeutic agent is an immune checkpoint inhibitor.63.The method of claim 62, wherein the at least one additional therapeutic agent is an inhibitor of PD-1.64.The method of any one of claims 54-63, wherein the method comprises administering to the subject an effective amount of the antibody, the masked antibody, or the pharmaceutical composition prior to a surgery or after a surgery to remove a solid tumor in the subject.65.A method inducing phagocytosis of cells expressing CTLA4, the method comprising contacting the cells expressing CTLA4 with an effective amount of the antibody of any one of claims 1-10, or the masked antibody of any one of claims 11-44.66.The method of claim 65, wherein the phagocytosis is antibody-dependent cellular phagocytosis (ADCP) .67.The method of any of claims 65-66, wherein the antibody, or the masked antibody, has a half maximal effective concentration (EC50) of less than 3 nM for inducing ADCP of cells expressing CTLA4.68.A method for depleting regulatory T cells, wherein the method comprises administering to the subject an effective amount of the antibody of any one of claims 1-10 or the pharmaceutical composition of claim 53.69.The masked antibody of any one of claims 11-35, wherein the antibody comprises an a human IgG1 Fc region, and wherein the human IgG1 Fc region is afucosylated.
